在癌症放射治疗中对心脏毒性的文献计量分析
Mengting Che1,2, Yuanqiong Duan1,2, Rutie Yin1,2
1Department of Obstetrics and Gynecology, West China Second Hospital of Sichuan University, Chengdu, Sichuan, China.
Frontiers in oncology
|April 24, 2024
概括
辐射诱导心脏病 (RIHD) 是癌症幸存者的一个严重问题. 这项文献计量研究绘制了RIHD研究趋势,突出了胸部癌症和临床前试验等关键领域,为未来的重点.
科学领域:
- 瘤学和心脏病学
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 放射治疗是一种重要的癌症治疗方法,但辐射诱导心脏病 (RIHD) 显著影响癌症幸存者的生活质量和生存率.
- 在瘤学中,RIHD是一个关键的挑战,需要全面了解研究趋势和未来方向.
研究的目的:
- 了解辐射诱导心脏病研究中的焦点和模式.
- 确定新兴的研究前沿和RIHD研究中的潜在新途径.
- 为 1990-2023 年期间的 RIHD 研究提供文献统计概述.
主要方法:
- 一次系统的搜索从Web of Science核心集合 (1990-2023) 中产生了1554个出版物.
- 用CiteSpace和VOSviewer进行了图表测量分析,以进行视觉映射.
- 分析包括国家,作者,期刊,参考文献和关键词,以确定研究热点.
主要成果:
- 关于RIHD的出版物输出显示了持续的增长趋势,在2013年显著增加.
- 美国是RIHD出版物的领先国家;国际辐射瘤学生物学物理杂志是最多产的期刊.
- 关键的研究集群包括乳腺癌,非小细胞肺癌,霍奇金淋巴瘤,临床前研究和心脏剂量,风险因素,癌症类型和质子疗法等关键词很突出.
结论:
- 未来的RIHD研究应该优先考虑胸癌和临床前试验.
- 有效管理RIHD需要预防,持续监测,及时诊断和及时治疗,以改善癌症幸存者的结果.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Hazard Ratio
115
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
115
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


